4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Different Epidermal Growth Factor Receptor (EGFR) Agonists Produce Unique Signatures for the Recruitment of Downstream Signaling Proteins.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The EGF receptor can bind seven different agonist ligands. Although each agonist appears to stimulate the same suite of downstream signaling proteins, different agonists are capable of inducing distinct responses in the same cell. To determine the basis for these differences, we used luciferase fragment complementation imaging to monitor the recruitment of Cbl, CrkL, Gab1, Grb2, PI3K, p52 Shc, p66 Shc, and Shp2 to the EGF receptor when stimulated by the seven EGF receptor ligands. Recruitment of all eight proteins was rapid, dose-dependent, and inhibited by erlotinib and lapatinib, although to differing extents. Comparison of the time course of recruitment of the eight proteins in response to a fixed concentration of each growth factor revealed differences among the growth factors that could contribute to their differing biological effects. Principal component analysis of the resulting data set confirmed that the recruitment of these proteins differed between agonists and also between different doses of the same agonist. Ensemble clustering of the overall response to the different growth factors suggests that these EGF receptor ligands fall into two major groups as follows: (i) EGF, amphiregulin, and EPR; and (ii) betacellulin, TGFα, and epigen. Heparin-binding EGF is distantly related to both clusters. Our data identify differences in network utilization by different EGF receptor agonists and highlight the need to characterize network interactions under conditions other than high dose EGF.

          Related collections

          Author and article information

          Journal
          J. Biol. Chem.
          The Journal of biological chemistry
          1083-351X
          0021-9258
          Mar 11 2016
          : 291
          : 11
          Affiliations
          [1 ] From the Department of Biomedical Engineering and Center for Biological Systems Engineering and.
          [2 ] Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110 and.
          [3 ] the Department of Biochemistry and Biophysics, Graduate Group in Biochemistry and Molecular Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104-6059.
          [4 ] From the Department of Biomedical Engineering and Center for Biological Systems Engineering and knaegle@wustl.edu.
          [5 ] Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110 and pike@biochem.wustl.edu.
          Article
          M115.710087
          10.1074/jbc.M115.710087
          26786109
          0003aacc-ac17-4af2-89ec-53e3cf13cb35
          © 2016 by The American Society for Biochemistry and Molecular Biology, Inc.
          History

          cancer biology,epidermal growth factor (EGF),epidermal growth factor receptor (EGFR),growth factor,receptor tyrosine kinase,systems biology

          Comments

          Comment on this article